Patent SG-11201908580X-A (SG)
Title: Npra agonists, compositions, and uses thereof
Inventor: CASTILLO GERARDO
IPC: C07K1/107
Filed: 2018-03-21
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I ill mu °million °nolo oimIE (10) International Publication Number WO 2018/175534 Al PCT N 00 O O (51) International Patent Classification: C07K 1/107 (2006.01) CO7K 14/47 (2006.01) CO7K 14/58 (2006.01) (21) International Application Number: PCT/US2018/023491 (22) International Filing Date: 21 March 2018 (21.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/475,147 22 March 2017 (22.03.2017) US (71) Applicant: PHARMAIN CORPORATION [US/US]; 11812 North Creek Parkway, N., Suite 101, Bothell, WA 98011 (US). (72) Inventors: CASTILLO, Gerardo, M.; c/o Pharmain Cor- poration, 11812 North Creek Parkway, N., Suite 101, Both- ell, WA 98011 (US). NISHIMOTO-ASHFIELD, Akiko; c/o Pharmain Corporation, 11812 North Creek Parkway, N., Suite 101, Bothell, WA 98011 (US). BOLOTIN, Elijah; c/ o Pharmain Corporation, 11812 North Creek Parkway, N., Suite 101, Bothell, WA 98011 (US). (74) Agent: ZHENG, Juan; Christensen O'Connor Johnson Kindness PLLC, 1201 Third Avenue, Suite 360, Seattle, WA 98101-3029 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: NPRA AGONISTS, COMPOSITIONS, AND USES THEREOF (57) : This disclosure provides a natriuretic peptide derivative of Formula (I), and to compositions including a natriuretic peptide derivative of Formula (I), (fatty acyl),-(B) x -(G) y -NP (I), wherein: z is 1, xis an integer from 2 to 4 and y is 3; or z is 0, xis an integer from 0 to 4 and y is an integer from 1 to 3; fatty acyl comprises from 12 to 24 (e.g., 12 to 18) carbons atoms; B is lysine or arginine; G is glycine; NP is a natriuretic peptide; if present, (fatty acyl) z is covalently linked to the N-terminus of (B) x ; (fatty acyl),-(B) x - is covalently linked to the N-terminus of (G) y ; and (fatty acyl),-(B) x (G) - is covalently linked to the N-terminus of NP. y The natriuretic peptide derivative according to the disclosure, and compositions thereof, are useful in the treatment of diseases such as hypertension, vascular congestion, and heart disease.